Around 2· 5 million deaths and more than 110 million COVID-19 cases have been reported
globally. Although it initially appeared that HIV infection was not a risk factor for COVID-19 or …

Antiretroviral therapies efficiently block HIV-1 replication but need to be maintained for life.
Moreover, chronic inflammation is a hallmark of HIV-1 infection that persists despite …

Abstract Human Immunodeficiency Virus (HIV) poses a significant global health challenge,
necessitating a deeper comprehension of the immune responses engaged in infection. B …

There is an urgent need to understand the nature of immune responses against SARS-CoV-
2, to inform risk-mitigation strategies for people living with HIV (PLWH). Here we show that …

Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …

Background: The relationship between HIV (human immunodeficiency virus) and COVID-19
clinical outcome is uncertain, with conflicting data and hypotheses. We aimed to assess the …

Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are highly effective at inducing protective immunity. However, weak antibody …

The fruit fly, Drosophila melanogaster, has been used to understand fundamental principles
of genetics and biology for over a century. Drosophila is now also considered an essential …

B cells play a central role in antiviral and antiparasitic immunity, not only as producers of
antibodies, but also as APCs and mediators of inflammation. In this study, we used 16-color …

Combination antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV)
infection has proven remarkably successful–for those who can access and afford it–yet HIV …